Is Medicamen Organ. overvalued or undervalued?

As of 4 November 2025, Medicamen Organ. has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its key financial ratios, including a PE ratio of 11.91, an EV to EBITDA of 8.62, and a ROCE of 12.71%. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 35.41, while Cipla, which is rated attractive, has a PE ratio of 22.35. The valuation metrics suggest that Medicamen Organ. is trading at a premium relative to its financial performance, especially when compared to peers like Dr. Reddy's Labs, which has a PE ratio of 17.36 and is rated attractive. Additionally, the company's stock has underperformed the Sensex significantly, with a year-to-date return of -38.22% compared to the Sensex's gain of 8.26%. This further reinforces the conclusion that Medicamen Organ. is currently overvalued in the market.